Particle Therapy 2017

RADCOMP

CONSORTIUM

Re-irradiation:

➢

Considered strong indication.

➢

Multiple trials ongoing

➢

Issue: “cumulative dose of normal tissue” – how to deal with prior dose 1

year or 20 years ago (OAR dose constraint definition)

➢

Issue: Appropriate patient selection –i.e. who will benefit considering the

risks?

Example: Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):819-27.

Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam

therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival

outcomes.

McAvoy S1